Results from the SACHI Phase III trial confirm the efficacy of MET inhibition in advanced NSCLC patients with acquired MET amplification after EGFR-TKI treatment. The savolitinib and osimertinib combination was approved in China in June 2025. The trial showed a significant improvement in progression-free survival with the combination compared to chemotherapy. The combination also demonstrated a higher objective response rate and disease control rate. The safety profile was tolerable, with no new safety signals observed. MET aberrations play a critical role in NSCLC, affecting a significant percentage of patients globally. ORPATHYS® is a selective MET TKI approved in China for treating NSCLC with MET exon 14 skipping alteration. It’s also approved for patients with EGFRm-positive NSCLC with MET amplification post-EGFR TKI therapy. TAGRISSO® is a proven EGFR-TKI used in NSCLC, showing improved outcomes in late and early-stage disease. The combination of ORPATHYS® and TAGRISSO® offers a promising treatment strategy for NSCLC patients with resistance to third-generation EGFR TKIs. Multiple Phase III trials are underway to study this combination in different patient populations, demonstrating high efficacy and safety. HUTCHMED is dedicated to developing targeted therapies for cancer treatment. HUTCHMED focuses on developing drug candidates for patients worldwide, with three medicines already marketed in China and globally approved. The company’s first medicine is approved in the US, Europe, and Japan. For more information, visit www.hutch-med.com. The press release contains forward-looking statements about ORPATHYS® and its clinical development, including potential risks and uncertainties. Investors are advised to review the risks associated with the statements. The release also provides contacts for investor and media inquiries. Additionally, the press release includes medical information about products and a fact sheet on all cancers from the World Health Organization. 1. Researchers have discovered a new species of dinosaur in Argentina. The dinosaur, named Llukalkan aliocranianus, had large eyes, sharp teeth, and a keen sense of smell.

2. The United States has surpassed the milestone of administering 100 million doses of the COVID-19 vaccine. This achievement comes as the country continues to ramp up its vaccination efforts.

3. In business news, Tesla has announced plans to build a new electric vehicle manufacturing plant in India. The plant is expected to create thousands of jobs and boost the country’s electric vehicle industry.

4. A new study has found that eating a diet high in fruits and vegetables can lower the risk of developing dementia. The study, published in the journal Neurology, highlights the importance of a healthy diet for brain health.

5. In sports news, tennis star Serena Williams has announced her retirement from professional tennis. Williams, who has won 23 Grand Slam titles, cited health reasons for her decision to step away from the sport.

Read more at 1. Apple announces new iPhone 13 lineup with improved cameras, faster processors, and longer battery life. – CNBC

2. Pfizer reports promising results from COVID-19 vaccine trials in children ages 5 to 11, showing strong immune response and minimal side effects. – Wall Street Journal

3. Amazon faces backlash over reports of harsh working conditions in its warehouses, with employees alleging long hours, strict quotas, and lack of breaks. – Reuters

4. Tesla unveils plans for new electric vehicle production facility in Texas, expected to create thousands of jobs and boost local economy. – CBS MarketWatch

5. Facebook introduces new safety features to combat online bullying and harassment, including enhanced reporting tools and AI-powered detection algorithms. – Barchart: HUTCHMED Highlights Publication of Phase III SACHI Results